Parkinson disease: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• SNCA 10
• LRRK2 7
• NRF2 1
• GBA1 13
• NLRP3 1
• PINK1 1
• AKT 0
• PI3K 0
• GLP-1 0
• STING 0
• BDNF 1
• mTOR 0
• SIRT1 0
• TLR4 0
• PPAR 0
• AMPK 1
• TP53 0
• GPX4 0
• MAPK 0
• MAPT 0
• TNF 0
• APOE 1
• HMGB1 0
• JNK 0
• ERK 0
• HSP90 1
• JAK 0
• STAT3 0
• TREM2 0
• HDAC 0
• TDP-43 1
• NMDA 0
• TFEB 0
• HIF-1 1
• IL-1 0
• PARP 0
• CTNNB1 0
• GIP 0
• IL-17 0
• PCSK9 0
• ACE2 0
• AQP4 0
• BCL-2 0
• CSF1R 0
• FTO 0
• PKM2 0
• SGLT2 0
• CD38 0
• COX-2 0
• DPP-4 0
• G6PD 0
• IDO1 0
• PDE4 0
• PTEN 0
• YAP 0
• ALK 0
• APP 0
• ATM 0
• BACE1 0
• C9orf72 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Multimodal AI-based Clinical prOgnostic Models for PArkinson's Symptoms progression and Subtyping (mAIcompass)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €435,842· until Nov 2030· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Lithuania· EU contribution €196,976· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Multi-scAle high-order neTwork modelling in the stUdy of human aging: A data-dRiven perspectIve using Topology and geometrY (MATURITY)

  Institut National de Recherche En Informatique Et Automatique· Le Chesnay Cedex, France· EU contribution €226,421· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  ENGINEERING NANOPARTICLE-WATER COUPLING; ionic, hypoxic, logic and molecular contrast switches (WATERGATING)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €2,113,066· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Single-vesicle PlAtform for Real-Time detection of membrane-catalyzed Aggregation and transmission (SPARTA)

  Aarhus Universitet· Aarhus C, Denmark· EU contribution €1,500,000· until Nov 2031

  The disease is named only in the funder's project summary, not in the title.

5 of 94 running projects, newest first. Listed amounts together: €184.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 19
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 15
• Gene Expression Profiling 76
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 7
• Exome Sequencing 12
• Proteomics 70
• Metabolomics 35
• Mass Spectrometry 12
• Flow Cytometry 4
• Immunohistochemistry 50
• Liquid Biopsy 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 103
• Magnetic Resonance Imaging 369
• Machine Learning 141
• Deep Learning 72
• Cohort Studies 185
• Genome-Wide Association Study 83

• Longitudinal untargeted metabolomics of cognitive impairment in Parkinson's disease.

  Alzheimers Dement, Oct 2026

• Exploring metabolic candidates and inflammatory mediation in Parkinson's disease: a pilot integrative metabolomics and Mendelian randomization study.

  PeerJ, Sept 2026

• Spatial multi-omics reveals disease-associated oligodendrocytes and metabolic dysregulation in male Parkinson's disease mouse models.

  Nat Commun, Sept 2026

• Spatial multi-omics reveals OAT-associated arginine-proline metabolic remodeling in Paraquat-induced Parkinsonian and depression-like phenotypes.

  Ecotoxicol Environ Saf, Sept 2026

• Beyond bacteria: a multi-omics view of the gut-brain axis in Parkinson's disease.

  Front Cell Infect Microbiol, Sept 2026

• Association of pre-clinical depressive symptoms and its plasma metabolomic signature with Parkinson's disease: a community-based longitudinal study.

  Transl Psychiatry, Aug 2026

• Complementary UV-MALDI and IR-MALDESI Imaging Expand Metabolomic Coverage in the 6-OHDA Rat Model of Parkinson's Disease.

  J Am Soc Mass Spectrom, Aug 2026

• Plasma LC-HRMS metabolomics in parkinsonian syndromes: comparative evaluation of sample preparation protocols for exploratory metabolic signatures.

  Anal Bioanal Chem, Jul 2026

• Metabolomic signatures for diagnosis and clinical severity in Parkinson's disease.

  EBioMedicine, Jul 2026

• Metabolomic signatures of brain aging: A multimodal and genetic study.

  Mol Psychiatry, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.